Application of B cell immortalization for the isolation of antibodies and B cell clones from vaccine and infection settings

Kristin L. Boswell1*, Timothy A. Watkins1, Evan M. Cale1, Jakob Samsel1-2, Sarah F. Andrews1, David R. Ambrozak3, Jefferson I. Driscoll1, Michael A. Messina1, Sandeep Narpala1, Christine S. Hopp3, Alberto Cagigi1, Joseph P. Casazza3, Takuya Yamamoto1, Tongqing Zhou1, William R. Schief4, Peter D. Crompton5, Julie E. Ledgerwood1, Mark Connors5, Lucio Gama1, Peter D. Kwong1, Adrian McDermott1, John R. Mascola1 and Richard A. Koup1

1Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States, 2Institute for Biomedical Sciences, George Washington University, Washington, DC, United States, 3Malaria Infection Biology and Immunity Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, United States, 4Department of Immunology and Microbial Science, IAVI Neutralizing Antibody Center and Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, The Scripps Research Institute, La Jolla, CA, United States, 5HIV-Specific Immunity Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States

The isolation and characterization of neutralizing antibodies from infection and vaccine settings informs future vaccine design, and methodologies that streamline the isolation of antibodies and the generation of B cell clones are of great interest. Retroviral transduction to express Bcl-6 and Bcl-xL and transform primary B cells has been shown to promote long-term B cell survival and antibody secretion in vitro, and can be used to isolate antibodies from memory B cells. However, application of this methodology to B cell subsets from different tissues and B cells from chronically infected individuals has not been well characterized. Here, we characterize Bcl-6/Bcl-xL B cell immortalization across multiple tissue types and B cell subsets in healthy and HIV-1 infected individuals, as well as individuals recovering from malaria. In healthy individuals, naïve and memory B cell subsets from PBMCs and tonsil tissue transformed with similar efficiencies, and displayed similar characteristics with respect to their longevity and immunoglobulin secretion. In HIV-1 viremic individuals or in individuals with recent malaria infections, the exhausted CD27-CD21- memory B cells transformed with lower efficiency, but the transformed B cells expanded and secreted IgG with similar efficiency. Importantly, we show that this methodology can be used to isolate broadly neutralizing antibodies from HIV-infected individuals. Overall, we demonstrate that Bcl-6/Bcl-xL B cell
immortalization can be used to isolate antibodies and generate B cell clones from different B cell populations, albeit with varying efficiencies.

**KEYWORDS**

B cell, immortalization, chronic infection, vaccination, malaria, HIV-1, influenza, antibody

---

**Introduction**

The isolation and characterization of antibodies from infection settings and vaccine trials in both humans and animal models can inform rational vaccine development. A better understanding of neutralizing antibodies, including their longitudinal maturation and binding specificity can aid in the development of new antigens and vaccine regimens. In addition, several neutralizing antibodies have either been approved for use, or are currently being tested for use as therapeutics to prevent or treat infectious diseases, such as in the cases of Ebola virus, respiratory syncytial virus (RSV), SARS-CoV-2 and Human Immunodeficiency virus (HIV) (1–4). Thus, efficient strategies to isolate antibodies from memory B cells following infection or vaccination are needed to not only inform future vaccine design, but also to identify novel therapeutics.

Multiple strategies exist to isolate antigen-specific B cells (5). One strategy includes using a recombinant fluorophore-labeled antigen probe to isolate antigen-specific B cells by flow cytometry for subsequent sequencing of the VH region (6, 7). While this strategy enriches for B cells based on antigen binding, antibody function can only be tested after antibody sequencing, cloning, expression and purification. Another method relies on the culture of B cells in vitro, where after 10–14 days of culture with cytokines and CD40 Ligand, activated B cells secrete immunoglobulin into culture supernatant and differentiate into plasma cells before cell death (8). This strategy enables screening for antibody function using immunoglobulin-containing culture supernatant, but the small-scale volume of culture supernatant available limits the breadth of screening that can be performed.

An alternative method that can combine both antigen-binding for B cell enrichment and screening of immunoglobulin-containing culture supernatant for antibody function has been applied to isolate rare antibodies from IgG+ and IgM+ memory B cells in PBMCs (9–11). This method relies on the retroviral expression of the transcription factor Bcl-6 and anti-apoptotic molecule Bcl-xL in primary memory B cells. When cultured in the presence of IL-21 and CD40 ligand, memory B cells transformed by Bcl-6 and Bcl-xL survive long-term in vitro, secrete antibodies into the culture supernatant, and continue to express the B cell receptor (BCR) on the cell surface (9). Thus, Bcl-6/Bcl-xL immortalization of memory B cells provides a flexible tool for antibody isolation where one can enrich for antigen-specific B cells by flow cytometry using a fluorophore-labeled antigen probe, and also screen for antibody function with a renewable source of culture supernatant.

The efficiency and application of Bcl-6 and Bcl-xL expression in specific B cell subsets has not been fully explored, and in select conditions this technology may be limited. Some level of B cell activation and proliferation must occur in vitro to enable retroviral transduction and Bcl-6 and Bcl-xL expression. Hence, B cell subsets that have a limited ability to proliferate and/or readily undergo in vitro cell death may not be as amenable to B cell transformation.

For example, in cases where biopsy samples or fine needle aspirates of draining lymph nodes are available, antigen-specific B cell responses from B cell follicles and germinal centers could be studied. However, germinal center B cells isolated from secondary lymphoid organs (SLO) more readily undergo cell death during in vitro culture and antibody discovery techniques that rely on long-term B cell culture may be limited (12). In chronic infection settings such as HIV-1, malaria or tuberculosis, the memory B cell population characterized by low expression of CD27 and CD21, such as HIV-1, malaria or tuberculosis, the memory B cell population characterized by low expression of CD27 and CD21, can comprise up to 40-50% of the memory B cell pool in PBMCs (13–17). In general, CD27 CD21- B cells are characterized by the high expression of inhibitory receptors and have an impaired ability to proliferate and produce antibodies when stimulated (13, 18). Nevertheless, HIV- and malaria-specific B cells can be found within CD27 CD21- B cell subsets, so isolation and characterization of antibodies from these subsets is of interest (19, 20).

In addition to antibody isolation from memory B cell subsets, immortalized B cells can be used for other applications such as the characterization of naïve B cell repertoires, as has been described for HIV-1-specific precursor B cells (21), as well as the generation of B cell clones that can serve as experimental controls. Clonal B cell lines can serve as valuable tools in the development of new reagents and assays. As novel antigens are developed to serve as probes for flow cytometric isolation and characterization of antigen-specific B cells, immortalized clones can function as controls for testing probe sensitivity and specificity, as well as being used to determine the level of detection when sorting rare B cells by flow cytometry.
Here, we explore the efficacy of Bcl-6 and Bcl-xL-mediated B cell immortalization to isolate B cell clones and antibodies from naïve and memory B cell subsets obtained from PBMCs and tonsil tissue. In addition, we compare the efficiency of Bcl-6/Bcl-xL B cell immortalization of CD27+CD21+ and CD27−CD21− B cells from HIV-1-infected individuals and from malaria convalescent individuals, and demonstrate a strategy to isolate HIV-1-specific neutralizing antibodies by combining Bcl-6/Bcl-xL B cell immortalization with the TZM-bl neutralization assay. Overall, we found Bcl-6 and Bcl-xL-mediated B cell immortalization to be a valuable tool to isolate antibodies and B cell clones in both vaccine and chronic infection settings.

Materials and methods

Human subjects

Peripheral blood mononuclear cells (PBMC) from healthy subjects were obtained from donors participating in the NIH research apheresis program. Tonsil cells were acquired from discarded anonymized specimens from Children’s National Medical Center (CNMC) with the approval from the CNMC Institutional Review Board as determined by the CNMC Institutional review board and did not constitute human subjects research as determined by the CNMC Institutional Review Board. Samples from the H7N9 influenza vaccine study (VRC 315; ClinicalTrials.gov; NCT02206464), which was a randomized phase I clinical trial in healthy adults designed to study the safety and immunogenicity of prime-boost vaccination regimens, were obtained through the VRC clinic (22–24). Informed consent was obtained from each volunteer and approved by the Institutional Review Board at NIAID, NIH. PBMC samples from three HIV-1-infected donors were also obtained through the Vaccine Research Clinic, while PBMCs from HIV-1-infected individuals with broadly neutralizing sera (patient 44 and donor N90) have been described previously (25, 26). All donors provided informed consent and studies were approved by the Institutional Review Board at NIAID, NIH. PBMC samples collected one week after treatment of the first febrile malaria episode were obtained from a Malian cohort as previously described (27), and was approved by the Ethics Committee of the Faculty of Medicine, Pharmacy and Dentistry at the University of Sciences, Technique, and Technology of Bamako, and the Institutional Review Board of NIAID, NIH (ClinicalTrials.gov; NCT0132258).

Reagents

pLZRS-IREs-GFP was kindly provided by Lynda Chin (Addgene plasmid # 21961; http://n2t.net/addgene:21961) (28). The human codon-optimized Bcl6-P2A-human codon-optimized Bcl-xL insert was synthesized using GeneArt (ThermoFisher) and cloned into pLZRS-IREs-GFP. 3T3-mCD40L cells were cultured and irradiated (5000 rads) as described previously (8). GP2-293 retroviral packaging cells and the p10A1 envelope vector were purchased from Clontech. Lipofectamine 3000 was purchased from ThermoFisher and Polybrene was purchased from Sigma. Cell culture reagents, including DMEM, IMDM, 100X Penicillin/Streptomycin/Glutamine were purchased from Gibco. Probes to detect antigen specific B cells against influenza (H7 and H3 HA), CD4-binding site antibodies against HIV-1 (RSC3 and deltaRSC3) and to detect VRC01-class precursor B cells (eOD-GT8 and eOD-GT8 knockout monomers) were generated and conjugated to fluorochromes as previously described (21, 23, 29–31).

Human IL-21 production

Human IL-21 was produced at the Vaccine Research Center. To express human interleukin-21 (IL21), (UniProtKB Q9HBE4) with a C-terminal thrombin cleavage site, an 8xHisTag and a TwinStrep tag the gene was synthesized and cloned into a mammalian expression vector pVRC8400. The plasmid was transiently transfected into freeStyle293F cells (Thermo Fisher). Protein was purified from filtered cell culture supernatant by Ni-NTA affinity column first and then by a StrepTactin (IBA) column.

B cell staining and sorting

To sort B cell populations from PBMC and tonsil cells (Figure 1), cells were first stained with violet fluorescent dye (Invitrogen) to demarcate dead cells, and then surface stained with an antibody cocktail. The antibodies used include: CD3 H7 APC (clone SK7; BD Biosciences), IgM PE-CF594 (clone G20-127; BD Biosciences), IgG PE-Cy5 (clone G18-145; BD Biosciences), CD20 BV570 (clone 2H7; Biolegend), CD19 BV785 (clone HIB19; Biolegend), IgD PE (Southern Biotech) and CD38 Alexa680 (clone OKT10; conjugated at the VRC). Sorted bulk B cell populations were activated and transduced. To isolate VRC01 precursor B cells, naïve cells (CD27 IgD+) were first stained with violet fluorescent dye and subsequently incubated with antibodies CD19 BV785, CD27 PC5 (clone 1A4CD27; Beckman Coulter), IgD PE and IgG BV605 (clone G18-145; BD Biosciences). Four days following transduction cells were stained with eOD-GT8 probes (labeled with APC or BV421) and the knockout eOD-GT8 probe (BV605) and GFP eOD-GT8+ cells were sorted into microplates containing irradiated CD40L feeder cells and IL-21 at 1 cell per well for clonal expansion and sequencing. To generate influenza-specific B cell clones, PBMC were stained with violet fluorescent dye and
CD3 BV785, CD19 ECD (clone J3-119; Beckman Coulter), CD20 APC-Cy7 (clone 2H7; Biolegend) and IgG Alexa700 (G18-145; BD Biosciences), sorted, transduced and subsequently stained with CD19 ECD and fluorochrome-conjugated probes to detect H3 HA and/or H7 HA specific B cells. GFP+HA+ B cells were sorted into microculture plates at 1 cell per well and cultured as described above. To compare B cell immortalization efficiency in B cell subsets from HIV-1-infected donors and donors recovering from malaria, cells were first surface stained, sorted in bulk, transduced and GFP+ B cells were sorted into microculture plates at 2 cells per well. Antibodies used for surface staining include CD20 APC-Cy7, CD19 BV785 (G18-145; BD Biosciences), CD10 PE-Cy5 (clone HI10a; BD Biosciences), IgG Alexa700, CD27 BV650 (clone 0323; Biolegend) and CD21 PE-Cy7 (clone B-ly4; BD Biosciences). All surface stains were incubated with the appropriate antibody cocktails for 20 minutes at room temperature and B cells were sorted using a modified FACS Aria. Flow cytometry data were analyzed in Flowjo v10.8.1 or v 9.9.6 (TreeStar).

**B cell isolation and activation**

B cell populations from PBMC or tonsils were sorted as described above and cultured in 12-well tissue culture plates in 1 mL of I10 medium (IMDM (Gibco) with glutamine, 10% FBS, supplemented with Penicillin, Streptomycin, Glutamine). Wells
contained 1 x 10^4 to 2 x 10^5 B cells, 2 x 10^5 irradiated 3T3-msCD40L cells and 25 ng/mL human IL-21. Cells were cultured for 36 to 48 hours at 37°C and 5% CO2 before retroviral transduction.

**Pseudotyped retrovirus generation**

5 x 10^6 GP2-293 packaging cells (Clontech) were plated in a 10 cm dish containing D10 medium (DMEM supplemented with 10% FBS, penicillin, streptomycin and glutamine). 24 hours after plating, 25 μg of the retroviral expression vector (pLZRS-human codon-optimized Bcl6-P2A-human codon-optimized BclxL-IRES-GFP) and 5 μg of the envelope vector (p10A1; Clontech) were transfected into GP2-293 cells using Lipofectamine 3000 (ThermoFisher) according to the manufacturer’s instructions. After 24 hours, the cells were supplemented with fresh D10 media. Retroviral supernatant was harvested 48 hours post-transfection, replaced with fresh D10 and again harvested 72 hours post-transfection.

**Retroviral transduction of activated B cells**

B cells that had been activated for 36-48 hours were transduced with fresh viral supernatant containing polybrene (4 μg/mL). Briefly, 1 mL I10 media was removed from the well of the 12-well plate and replaced with 1 mL fresh viral supernatant (48-hour retroviral supernatant) containing polybrene. The plate was centrifuged at 1200xg for 1 hour at 32°C, rested for 1 hour at 37°C and 5% CO2 before the viral supernatant was replaced with fresh D10 and again harvested 72 hours post-transfection.

**Transformed B cell culture**

Transformed B cells cultured in bulk were maintained in 12-well plates. Cells were split 1:4 every 3-4 days into wells containing 2 x 10^5 3T3-msCD40L cells and 25 ng/mL human IL-21 in 1mL of I10. Cell counts were measured by flow cytometry using counting beads (BD Biosciences) and data were collected on a modified LSRII or a modified FACSymphony. For microculture, transformed B cells were sorted 3 days following transduction. B cells were then rested for ~3 days before determining transduction efficiency by flow cytometry and sorting for microculture.

**IgG and IgM ELISA**

Concentrations of total IgG and IgM in the culture supernatant were determined by ELISA (ThermoFisher) according to the manufacturer’s instruction.

**Immunoglobulin amplification and sequencing**

B cells were dry-sorted into a 96-well PCR plate at 1-2 cells per well and multiplex polymerase chain reaction (PCR) was used to amplify the heavy and/or light chain sequences as previously described (7). PCR products were sequenced by ACGT, Inc., Eurofins or Genewiz and analyzed using Geneious Prime and the IMGT database (32, 33).

**In vitro mutation analysis**

To characterize the accumulation of mutations during in vitro culture, IgG+ B cells from PBMC of uninfected individuals and germinal center IgG+ B cells from tonsil tissue were transduced. Four days post-transduction, GFP+ B cells were sorted at one cell per well into 384-well microculture plates. Following 8 days of microculture, clonal GFP+ B cells from selected wells were harvested and sorted at 1 cell per well into a PCR plate for BCR sequencing (48 total wells for each clone), and the remaining clonal B cells were placed back into culture. The same selected clonal B cells were again harvested on day 24 and sorted into PCR plates at 1 cell per well for BCR sequencing (96 total wells for each clone). The sequences from the VH genes were aligned using Geneious software to generate a consensus sequence and each individual sequence was analyzed for differences from the consensus sequence. Mutations deviating from the consensus sequence were confirmed by analyzing sequence chromatograms and assessing the quality of chromatogram peaks relative to the basecall recorded. Only mutations with clear, single color, high confidence sequence peaks were considered as actual mutations.

**Phosphoflow to measure phosphorylation of ERK**

HA-specific immortalized B cell clones were resuspended in IMDM + 1% FBS and stimulated for 2 minutes at 37°C with HA before harvesting the final supernatant and either freezing the cultures in the 384-well plate (50ul freezing media per well (FBS + 10% DMSO)), or expanding selected wells to 96-well tissue culture plates.
probes (250nM), anti-IgG F(\text{ab}')₂ (5 μg/mL; Southern Biotech) or anti-IgM F(\text{ab}')₂ (5 μg/mL; Southern Biotech). Cells were immediately fixed with pre-warmed paraformaldehyde (4% final concentration), incubated at 37°C for 10 minutes and pelleted by centrifugation. Cells were resuspended in cold Perm Buffer III (BD Biosciences), incubated on ice for 30 minutes and washed twice with stain buffer (PBS + 1% FBS). Cells were resuspended in stain buffer and incubated with anti-ERK1/2 (pT202/pY204 Alexa647) (BD Biosciences) for 30 minutes at room temperature. Cells were subsequently washed and data were collected on a modified LSRII (BD Immunocytometry Systems) and analyzed using Flowjo (TreeStar).

**BG505-SOSIP DS binding analysis of supernatants**

Standard MSD 384 well streptavidin coated SECTOR™Imager 2400 plates were blocked with 35 μL of 5% (W/V) MSD Blocker A and incubated for 1 hour at room temperature (RT) on a Heidolph Titramax 100 vibrational plate shaker at 650 rpm. All incubations in this assay were performed as described above. The plates were washed three times with 0.05%Tween PBS (wash buffer) and were coated with biotinylated BG505 SOSIP DS-FPV1 10ln QQ AVI protein (Biotin Trimer 7070 capture) at an optimized concentration of 1 μg/mL for 1 hour. 1% MSD Blocker A was used as the diluent in the assay. The test samples (B cell supernatants) were diluted 1 to 1 with assay diluent in dilution plates. After 1 hour of incubation, the plates were washed again with the wash buffer and the serial diluted test samples were added to MSD plates. After an hour of incubation with the samples, the plates were washed again, and SULFO-TAG conjugated goat anti-human secondary detection antibody was used for detection at an optimized concentration of 1 μg/mL. After an additional hour of incubation, the unbound secondary detection antibody was washed off the plates and the plates were read using 1X MSD Read Buffer on the MSD Sector Imager 2400.

**Antibody purification from B cell culture supernatants**

B cells from the CD27⁺CD21⁺ and CD27⁻CD21⁻ populations that displayed greater relative neutralization against pseudoviruses expressing HIV-1 envelopes BG505.T32N and MW965.26 in the TZM-bl microneutralization assay were expanded in serum free media hybridoma media (Gibco) that was supplemented with irradiated feeder cells and IL-21. Supernatants were concentrated and IgG was purified using Ab Spintrap columns (GE Healthcare/Cytiva).

**HIV-1 TZM-bl neutralization assays**

Screening small volumes of B cell culture supernatants for HIV-1 neutralizing activity was performed using the HIV-1 microneutralization assay as described (34). B cells from Pt.44 and donor N90 that displayed greater relative neutralization against the JRFL.JB pseudovirus in the microneutralization assay were cloned and expressed. Percent neutralization was calculated as: \([(\text{RLU virus with no Ab)} – (\text{RLU virus with Ab})]/(\text{RLU virus with no Ab}) \times 100. Neutralization breadth and IC50 and IC80 values were determined for HIV-1-specific antibodies against a panel of Env-pseudoviruses using TZM-bl target cells as previously described (35).

**Statistical analysis**

GraphPad Prism software was used for statistical analysis and to prepare figures. Statistical analysis was performed using paired t-tests, Wilcoxon matched-pairs signed rank tests or one-way ANOVA with Tukey’s multiple comparison test as indicated. Bars depict mean values with standard deviations shown.

**Results**

**Activation and transduction of multiple B cell subsets from PBMC and tonsil**

To better understand the application of Bcl-6 and Bcl-xL B cell transformation to different B cell subsets, we compared the efficiency of Bcl-6/Bcl-xL transformation of naïve and memory B cells isolated from human PBMCs, and naïve and memory subsets isolated from human tonsil. For PBMCs, we sorted IgD⁺ (naïve) and IgD-IgM-IgG⁺ (IgG⁺ memory) B cells and activated them in the presence of recombinant human IL-21 (25 ng/ml) and irradiated 3T3-msCD40-ligand (CD40L) feeder cells for 2 days (Figure 1A). We spinoculated (1200xg, 32°C, 1 hour) activated B cells with fresh viral supernatant supplemented with polybrené (4 μg/mL) on days 2 and 3 of activation (Supplemental Figure 1). On day 4 post-transduction we observed transduction efficiencies between 45-80% for both IgD⁺ and IgD⁻IgM⁻IgG⁺ B cell populations as determined by the expression of green fluorescent protein (GFP) (Figures 1C, E). For tonsil tissue, we sorted IgD⁺ (naïve) B cells, IgD⁻CD20⁺CD38⁺IgG⁺ (Germinal Center (GC) IgG⁺) B cells, and IgD⁻CD20⁺CD38⁻IgG⁻ (non-germinal center (Non-GC) IgG⁻) B cells and transduced the populations as described above (Figure 1B). Similar to B cell populations isolated from PBMCs of healthy subjects, we again observed transduction...
efficiencies between 45-80% for all B cell subsets based on GFP expression (Figures 1D, F).

In addition to determining the frequency of GFP+ B cells, we calculated the expansion of B cell subsets from the initial activation through 4 days post-transduction (6 days total). Overall, while we did observe differences between subjects, we found that the total number of CD19+ B cells expanded between 4-fold to 40-fold, with IgG+ B cells from the tonsil expanding less compared to naïve B cells (Figures 1E, F). Following transduction and expression of Bcl-6 and Bcl-xL, all GFP+ B cells continue to expand and to express surface immunoglobulin (Supplemental Figures 2A–C).

Microculture of transformed B cells

To evaluate the efficiency of transformed naïve and IgG+ memory B cell subsets to expand in microculture, and to determine the amount of immunoglobulin secreted, we compared microcultures of transformed B cells isolated from naïve and memory B cells from both PBMCs and tonsil tissue. Transduced B cells were sorted into 384-well microculture plates at 1, 2 or 5 GFP+ cells per well at four days post-transduction. Cultures were supplemented with fresh media, IL-21 and irradiated CD40L-feeder cells every four days. On day 24 of culture, we measured IgM and IgG concentrations in the culture supernatant of transformed naïve and memory B cells, respectively. When sorted at 1 cell per well, between 20 and 33% of the memory wells had detectable levels of IgG, while between 32 and 38% of the naïve wells had detectable levels IgM (Figure 2A). Within the positive wells, the median immunoglobulin concentration ranged from 0.39 μg/mL to 1.5 μg/mL for IgG with greater median concentrations for IgM at 7.3 to 8.3 μg/mL for PBMC and tonsil cells, respectively. Sorting 2 and 5 GFP+ B cells per well resulted in an increased frequency of positive wells at day 24 with a slight, but not significant increase in the median immunoglobulin concentration (Figure 2A).

Since B cell receptor sequencing of B cells and cloning of antibodies may not occur until after screening culture supernatants on day 24 or later, we explored whether or not B cell clones acquire mutations during long-term culture, as has been described for an immortalized RSV-specific B cell line (9). We sorted single IgG+ transformed B cells from both PBMCs and the tonsil germinatal centers into a microculture plate and sequenced individual B cells from the expanded clones both early during culture (day 8) and at the end of culture (day 24) (Figure 2B). Germinal center B cells were specifically chosen for analysis because they express high levels of activation-induced cytidine deaminase (AID) in vivo, which could result in more mutations during in vitro culture following transformation. After aligning the individual B cell sequences from each clone to determine the consensus sequence bioinformatically, we determined whether each individual sequence contained any base pair substitutions, or insertions/deletions compared to the consensus. The overwhelming majority of sequences acquired zero mutations at both day 8 and at day 24 of culture, although we did detect more sequences containing mutations on day 24 (PBMC IgG+ with zero mutations: mean 98.4% on day 8 vs 90.3% on day 24, p<0.05; Tonsil GC IgG+ with zero mutations: mean 93.7% on day 8 vs 90.1% on day 24, p<0.05) (Figure 2C; Supplemental Figures 3A, B). Interestingly, with the exception of one clone, germinatal center B cells did not acquire significantly more mutations compared to IgG+ B cells from PBMCs during the 24 day culture. The few acquired mutations consisted mostly of one or two base pair substitutions (Figure 2C; Supplemental Figures 3A, B). These results suggest that the frequency of mutations acquired during transformed B cell culture is almost negligible, and that the immunoglobulin sequence of the primary B cell can readily be determined by aligning multiple clonal B cell sequences to determine the consensus sequence.

Generation of antigen-specific naïve and IgG+ memory B cell clones

We next asked whether we could generate antigen-specific memory B cell clones from both naïve and memory B cell subsets. To generate naïve B cell clones, we isolated CD27- IgD+ B cells from PBMCs of a healthy donor and transduced the cells with the Bcl-6/Bcl-xL retroviral vector. Following transduction, we stained the cells with eOD-GT8, a probe that binds to precursor B cells of VRC01-class HIV-specific broadly neutralizing antibodies (bNAb) that target the CD4 binding site (21), and the eOD-GT8 knockout probe (eOD-GT8 KO), which has been mutated within the CD4 binding site and is used to avoid sorting off-target B cells (29) (Figure 3A). From the GFP+eOD-GT8 KO+ population we sorted the eOD-GT8+ B cells into a microculture plate at 1 cell per well. After allowing the B cells to expand, we sequenced the clonal B cells to determine their BCR sequence. Based on the sequence data we determined that clone IMMO-A1, which is of the VH1-2 family and contains a 5 amino acid long L-CDR3, is a VRC01 precursor B cell line (Figure 3B). Clone C1, which contains a VH1-2 sequence without a 5 amino acid long L-CDR3, and clone A2, which is not a member of the VH1-2 family, are also shown. After expansion and freeze/thaw, clone IMMO-A1 maintains its ability to bind to eOD-GT8. Thus, this methodology can be used to produce an immortalized cell line of a rare and highly specific B cell clone from the naïve B cell repertoire.

We also applied B cell immortalization to isolate antigen-specific memory B cell clones after influenza vaccination. To do so, we took PBMCs collected two weeks after a second dose of H7N9 MIV (22–24). To generate H7 HA-specific B cell clones we sorted IgG+ B cells from PBMCs and following transduction we stained the transduced cells with H7 HA and H3 HA fluorophore-conjugated probes, and subsequently sorted all H7 HA-positive B cells at 1 cell per well for microculture.
After clonal expansion we sequenced and characterized clones for binding to H7 and H3 HA, of which Clone 1 and Clone 2 are shown (Figure 3D). We found the HA clones maintained their specificity from the single cell sort through clonal expansion, with Clone 1 binding to both H7 and H3 HA, and Clone 2 binding to the H7 HA but not to the H3 HA (Figure 3D). In addition, we measured HA-specific B cell activation as detected by the ERK phosphorylation by flow cytometry, similar to what has been described for tetanus-specific B cells (9). Anti-IgG F(ab’)_2 and H7 HA promoted phosphorylation of ERK in both clones, whereas the H3 HA induced phosphorylation of ERK in only Clone 1 (Figure 3D). Thus, immortalized clones can be used to test whether immunogens not only bind to a specific B cell receptors but can also activate signalling through the B cell receptor.

Because the H7 HA-specific B cell repertoire has previously been characterized in these individuals, we compared the H7 HA-specific immortalized B cell repertoire to the previously
characterized repertoire (23). We compared the clonal overlap and VH gene usage of the H7 HA-specific B cells from immortalized and ex vivo sorted B cells from 3 donors at the same time point following vaccination. In general, large clonal expansions are detected by both methods with less overlap observed with infrequent clones (Supplemental Figure 4A). And while there are some differences in the VH gene usage amongst the H7 HA-specific clones, there is not a major skewing of the repertoire when comparing the ex vivo probe-sorted repertoire to that of the immortalized probe-sorted repertoire (Supplemental Figure 4B). Thus, this methodology can be used to produce and characterize immortalized B cell clones that are representative of the vaccine-specific memory B cell pool in healthy individuals.

**Immortalization of B cells from individuals with chronic infection**

In chronic infection settings, the CD27−CD21− B cell population, which has a markedly reduced ability to proliferate *in vitro*, increases in frequency within PBMCs. Since antigen-specific antibodies can be found within this population, we characterized the efficiency of immortalization within this population. We sorted the CD27−CD21− and CD27+CD21+ populations from 3 healthy individuals, 3 HIV-1-viremic individuals (viral loads: 385, 4503 and 608,544 copies/mL) and 4 individuals recovering from febrile malaria at one week after treatment (convalescence). Within the HIV-1-infected and
malaria convalescent donors, we observed that the *ex vivo* CD27 CD21\(^+\) population was indeed increased compared to healthy donors while the CD27\(^+\)CD21\(^-\) population was decreased (Figures 4A, B). We observed significant differences in the transduction efficiencies between the CD27\(^+\)CD21\(^+\) and CD27\(^+\)CD21\(^-\) population across all donors (p<0.0001) and differences across multiple subsets based on CD27 and CD21 expression (Figure 4C; Supplemental Figure 5A). We observed a similar trend with respect to the fold increase in total B cells during the transduction process, where the fold increase in B cell numbers of CD27\(^+\)CD21\(^+\) population was consistently lower compared to the CD27\(^+\)CD21\(^-\) population (p<0.005) (Figure 4D, Supplemental Figure 5B). On day 7 we analyzed the surface phenotype of the transduced (GFP\(^+\)) and non-transduced (GFP\(^-\)) populations and found that the GFP\(^+\) cells continued to express CD20 and surface IgG, with GFP\(^+\) cells losing expression of these markers (Supplemental Figure 5C). Interestingly, we found that the GFP\(^+\) cells expressed CD21 but little to no CD27 irrespective of the starting population. To evaluate the efficiency of B cell expansion and secretion in microculture, we sorted 2 GFP\(^+\) B cells per well into a 384-well plate and cultured the cells for 24 days. Although not statistically significant, we found the CD27\(^+\)CD21\(^+\) population tended to result in fewer IgG\(^+\) positive wells compared to the CD27\(^+\)CD21\(^-\) population, but that IgG\(^+\) wells contained similar median concentrations of IgG (Figures 4E, F; Supplemental Figure 5D).
Figures 5D–F). Thus, while the overall B cell expansion and transduction efficiency is lower for the CD27 CD21+ population, the transduced cells do maintain surface IgG expression and secrete antibodies.

In the HIV-1-infected individuals, we identified IgG-containing culture supernatants that bound to a soluble, HIV-1 envelope protein based on the BG505 sequence (BG505 SOSIP) in both the CD27+CD21+ and CD27 CD21+ populations (36) (Supplemental Figure 6A). After expanding B cells from the wells that showed binding to the BG505 SOSIP, and screening supernatants for neutralization against the BG505.T332N or the Tier1A MW965.26 pseudoviruses, we purified antibodies from 2 wells to further test for neutralizing activity (Supplemental Figure 6B). While well 1 failed to neutralize either the BG505.T332N or MW965.26 pseudoviruses upon further inspection, we did detect weak neutralization against the MW965.26 pseudovirus for well 2, which originated from the CD27 CD21+ B cell subset (Supplemental Figures 6C, D). These data demonstrate that HIV-1-specific antibodies can be isolated from the CD27 CD21+ population by B cell immortalization.

Isolation of broadly neutralizing antibodies from immortalized B cells

To determine if B cell immortalization can be used to isolate bNAbs from HIV-1-infected individuals, we applied the technology to donors from which bNAbs have previously been isolated. Antibody VRC38.01 was previously isolated from donor N90 while VRC13 was isolated from patient 44 (Pt.44) (25, 26). B cells were sorted and transduced from each donor, and on day 4–post transduction GFP+ cells that bound to the RSC3 probe (Pt.44) and JRFL.DS.SOSIP (N90) were sorted into 384-well plates at 2 cells per well to maximize the number of B cell positive wells and cultured for 23 to 31 days (Figure 5A). Single point neutralization screening was performed using supernatants from days 23, 27 and 31 of microculture against the JRFL.JB pseudovirus (Figure 5B). Cell lysates from wells with greater relative neutralization were sequenced and only one heavy chain and one light chain sequence was obtained from each positive well. Analysis of the antibody sequences indicates the antibody isolated from donor N90 (well 5J18) is a relative of VRC38, while the antibody isolated from Pt.44 (well 3E06) is related to VRC13 (Figure 5C). Of note, the immortalization procedure was repeated for Pt.44 and a second VRC13 relative was isolated (well E3). The antibody isolated from Donor N90 (well 5J18) utilizes the same V and J genes as VRC38.01 for both the heavy and light chains and shares the same CDRH3 and CDRL3 sequences. Similarly, the two antibodies isolated from Pt.44 share the same V and J genes for both the heavy and light chains as VRC13, and within the CDR3 regions residues that differ from VRC13 are highlighted in red (Figure 5C).

Single point neutralization assays were performed against a 31-virus panel for the three cloned antibodies and between 29 and 32% of viruses were neutralized by more that 50% (Figure 5D). The cloned antibodies, along with VRC13 and VRC38.01 were further tested for neutralization against a panel of 17 viruses that showed sensitivity in the single-point assay. The antibody isolated from well 5J18 showed similar potency and breadth as compared to VRC38.01, whereas the two antibodies isolated from Pt.44 display less potency and breadth as compared to VRC13 (Figure 5E). Overall, these studies serve as a proof-of-principle that B cell immortalization can be used to isolate bNAbs.

Discussion

While Bcl6/Bcl-xL B cell immortalization was first described in IgG+ and IgM+ memory B cell populations from PBMCs from healthy donors, and similar B cell immortalization methods have recently been described in cancer settings and applied to naïve B cells, an extensive comparison of the same Bcl6/Bcl-xL B cell immortalization protocol across multiple B cell subsets, including chronic infection settings, has not been done (9, 21, 37). Here, we characterized and applied Bcl-6/Bcl-xL B cell immortalization to multiple B cell subsets including naïve and memory B cell subsets from both lymphoid tissue and PBMCs in healthy and chronically-infected individuals. In our hands, we found Bcl-6/Bcl-xL B cell immortalization to be applicable across multiple B cell subsets, although with differing efficiencies amongst distinct B cell populations.

The application of B cell immortalization to B cell populations with a reduced capacity to proliferate and survive in vitro, such as CD27+CD21+ memory B cells and germinal center B cells, may provide an alternative means for antibody isolation from these populations, in lieu of traditional B cell culture. For example, although we found primary germinal B cells expanded less when cultured with IL-21 and CD40 Ligand when compared to other B cell subsets, we found that post-transduction, the immortalized B cells from this population expanded and secreted antibodies in similar amounts to that of immortalized IgG+ B cells from PBMC of healthy donors, suggesting that immortalization of germinal center B cells could serve as an alternative method to isolate rare antibodies from germinal centers of SLOs. In this regard, HIV-1-specific bNAbs were recently isolated from germinal center B cells of lymph nodes using an Epstein-Barr Virus-based immortalization strategy, demonstrating that rare antibodies can be isolated from germinal centers with B cell immortalization strategies (38). In chronic infection settings, we found that B cell immortalization can be applied to the CD27+CD21+ IgG+ population with similar efficiency to that seen in IgG+ memory B cells in uninfected individuals, but we observed decreased transduction and expansion of the CD27 CD21+ IgG+
population. Thus, if antibodies of interest are found within the CD27+CD21+ B cell population, this technique has a greater capacity to isolate the antibodies of interest, although antibodies can still be isolated from the CD27-CD21- population, as the immortalized B cells from this population do secrete antibodies and express surface immunoglobulin.

One of the greatest advantages of this technology is the flexibility of screening for both antibody binding and function with relatively large quantities of immunoglobulin-containing culture supernatant. In a traditional B cell culture method, where primary B cells are activated for 10 to 14 days before screening immunoglobulin-containing culture supernatant, a limited amount of functional screening can be applied. In the HIV-1 TZM-bl microneutralization assay, which screens primary B cell culture supernatants from 384-well culture plates for HIV-1 neutralizing antibodies, one can only test for neutralizing activity against one or two pseudoviruses due to limited supernatant volumes. Because immortalized B cells are continuously

---

**FIGURE 5**

Isolation of bNAbs from HIV-1-infected individuals. (A) Flow cytometry plots showing B cell binding to HIV-1-envelope specific probes after B cell transduction. (B) Percent neutralization of B cell culture supernatants against the JRFL pseudovirus following 23, 27 or 31 days of microculture. (C) Immunogenetic characterization of antibodies sequenced from wells identified as having greater relative neutralization. (D) Single point neutralization assays were performed against a 31-virus panel for the cloned antibodies. (E) IC50 and IC80 values were determined for the three identified antibodies using a panel of 17 pseudoviruses.
expanding, larger volumes of supernatant can be generated and screened against several pseudoviruses to assay for breadth before antibody sequencing and cloning. We were able to isolate a HIV-1-specific antibody from the CD27 CD21 population of a HIV-1-infected donor, where we first screened for binding to the HIV-1 envelope SOSIP trimer, with subsequent screening for neutralizing activity after expanding wells of interest. Importantly, we were also able to demonstrate this technology can be applied to isolate bNAbs from HIV-1-infected individuals by using a slightly different strategy where we combined B cell immortalization with the TZM-bl microneutralization assay and subsequently cloned the antibodies for further characterization. Both of these examples, along with our recent study in donors after malaria infection where we isolated MSP-specific IgM+ antibodies, can serve as a proof-of-concept to show that Bcl6/Bcl-xL immortalization can be applied to chronic infection settings to isolate antibodies of interest (39).

Because we did detect differences between B cell subsets during activation and following transduction, and because individual clones do expand at different rates, the utility of this methodology as a means to characterize the B cell repertoire is unclear. Using influenza vaccination as a model system, we compared the H7 HA-immortalized B cell repertoire to that of a previously characterized repertoire using the same samples and the same probes as bait as previously published (23). In general, both methodologies detected large clonal expansions but there was less overlap with rarer clones, with some clones detected with only ex vivo sorting, and others detected after immortalization and clonal expansion. And while some of these discrepancies can be attributed to the depth of sequencing, they may also be attributed to the variable efficiency of B cell immortalization in different B cell subtypes. In general, however, we did not detect a major bias in the immortalized H7 HA-specific B cell repertoire compared to the previously published ex vivo repertoire (23). Therefore, not only can B cell immortalization be used to isolate rare antibodies and generate B cell clones, it could also be used to study the B cell repertoire to a particular antigen.

As B cell clones are expanded for increased screening and analysis, one potential concern is whether the clones acquire mutations during the in vitro culture, and whether the final sequence of the desired clone represents the sequence of the primary B cell. In our experimental setting, while we did detect mutations during the microculture, we found these mutations to be minimal. Some of the mutations may be due to PCR error, although some certainly represent actual mutations as we observed more mutations on day 24 of culture compared to day 8 using the same sequencing protocol. Overall, we found that by sequencing several individual B cells from the same clone and aligning the sequences bioinformatically, we could determine the consensus sequence which likely represents the sequence of the original primary B cell. Of course, as clones are further expanded one should take into account the accumulation of additional mutations which may or may not be desired. Interestingly, we did not detect significant differences in the frequency of mutations acquired during in vitro culture for immortalized B cells isolated from PBMCs and immortalized B cells isolated from germinal centers. Its possible that B cell transformation itself, and/or the in vitro culture conditions result in similar AID expression between the immortalized B cell subsets.

In addition to serving as experimental controls to test for specificity and sensitivity of B cell probe binding, immortalized B cell clones can also be used to characterize the capacity of novel immunogens to induce B cell signaling. In combination with a high-throughput B cell activation assay, such as detection of phosphorylation of ERK by flow cytometry, libraries of immortalized B cell clones can be utilized to measure the diversity and specificity of the B cells that respond to the immunogen. The use of clonal B cell lines may also prove to be especially valuable in the HIV-1 vaccine field where novel immunogens are being designed to bind to and activate germline precursor B cells. Here, naïve precursor clonal B cell lines can serve as controls to characterize novel probes aimed to activate precursor B cells and to also test for assay specificity, sensitivity and reproducibility in the analysis of data from clinical trials.

As with any methodology, there are advantages and disadvantages to be considered before applying the technology, including the efficiency of the methodology. Overall, Bcl-6/Bcl-xL B cell immortalization is a valuable tool for antibody isolation and clonal B cell line development, and our results here show that it can be applied to different B cell populations, including populations that may be less amenable to long-term B cell culture.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by Institutional Review Board at NIAID, NIH; and the Ethics Committee of the Faculty of Medicine, Pharmacy and Dentistry at the University of Sciences, Technique, and Technology of Bamako. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

Author contributions

KB, TW, EC, JS, SA, CH, and AC helped design experiments. KB, TW, EC, DA, JD, MM and SN performed experiments and KB, TW, EC, JS, SA, LG and RK analyzed and interpreted the data.
KB wrote the manuscript and TW, EC, JS, SA, CH, TZ, WS, PC, LG, PK and RK edited the manuscript. SA, CH, AC, JC, TY, TZ, WS, PC, JL, MC, PK, AM and RK provided reagent resources or clinical samples and RK supervised the work. All authors contributed to the article and approved the submitted version.

**Funding**

This work was supported by the Bill and Melinda Gates Foundation (grant OPP1147555) and by the Intramural Research Program of the Vaccine Research Center, NIAID, NIH.

**Acknowledgments**

We would like to thank Drs. Nicole Doria-Rose and Rosemarie Mason for B cell culture advice and training on the liquid handling robots, and Dr. Guillaume Stewart-Jones for providing the JRFIL.DS.SOSIP. We would also like to thank Alida Taylor and Carmelo Chiedi for irradiating the 3T3-msCD40L cells and Siyj O’Dell and Steve Schmidt for providing the VRC01 antibody and the pSG3deltaEnv vector, and for the plasmids encoding the BG505.T332N and MW965.26 HIV-1 envelopes. We thank the VRC Flow Cytometry Facility as well as Margaret Beddall for help with flow cytometry instruments and in-house antibody conjugation.

**References**

1. The Antibody Society. *Therapeutic monoclonal antibodies approved or in review in the EU or US*. Available at: www.antibodysociey.org.

2. Julg B, Barouch D. Broadly neutralizing antibodies for HIV-1 prevention and therapy. *Semin Immunol* (2021) 51:101475. doi: 10.1016/j.smim.2021.101475

3. Stephenson KE, Barouch DH. Broadly neutralizing antibodies for HIV eradication. *Curr HIV/AIDS Rep* (2016) 13(1):31–7. doi: 10.1007/s11904-016-0299-7

4. Mahomed S, Garrett N, Baxter C, Abdool Karim Q, Abdool Karim SS. Clinical trials of broadly neutralizing human monoclonal antibodies for immunodeficiency virus prevention: A review. *J Infect Dis* (2021) 223(3):370–80. doi: 10.1093/infdis/jiaa377

5. Wilson PC, Andrews SF. Tools to therapeutically harness the human antibody response. *Nat Rev Immunol* (2012) 12(10):709–19. doi: 10.1038/nri3285

6. Scheid JF, Mouquet H, Feldhahn N, Walker BD, Pereyra F, Cutrell E, et al. A method for identification of HIV gp140 binding memory b cells in human blood. *J Immunol Methods* (2009) 343(2):65–7. doi: 10.1016/j.jim.2008.11.012

7. Tillier T, Meffe E, Yurasov S, Tsuji M, Nussenzweig MC, Wardemann H. Efficient generation of monoclonal antibodies from single human b cells by single cell RT-PCR and expression vector cloning. *J Immunol Methods* (2008) 329(1-2):112–24. doi: 10.1016/j.jim.2007.09.017

8. Huang J, Doria-Rose NA, Longo NS, Laub L, Lin CL, Turk E, et al. Isolation of human monoclonal antibodies from peripheral blood b cells. *Nat Protoc* (2013) 8 (10):1907–19. doi: 10.1038/nprot.2013.117

9. Kwakkenbos MJ, Diehl SA, Yasuda E, Bakker AQ, van Geelen CM, Lukens MV, et al. Generation of stable monoclonal antibody-producing b cell receptor-positive human memory b cells by genetic programming. *Nat Med* (2010) 16 (1):123–8. doi: 10.1038/nm.2071

10. Kwakkenbos MJ, Bakker AQ, van Helden PM, Wagner K, Yasuda E, Spits H, et al. Genetic manipulation of b cells for the isolation of rare therapeutic antibodies from the human repertoire. *Methods* (2014) 65(1):38–43. doi: 10.1016/j.ymeth.2013.07.002

11. Kwakkenbos MJ, van Helden PM, Beaumont T, Spits H. Stable long-term cultures of self-renewing b cells and their applications. *Immunol Rev* (2016) 270 (1):65–77. doi: 10.1111/imr.12395

12. Liu YJ, Mason DY, Johnson GD, Abbott S, Gregory CD, Hardie DL, et al. Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis. *Eur J Immunol* (1991) 21(8):1905–10. doi: 10.1002/eji.1830210819

13. Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, O’Shea MA, et al. Evidence for HIV-associated b cell exhaustion in a dysfunctional memory b cell compartment in HIV-infected viremic individuals. *J Exp Med* (2008) 205(8):1797–805. doi: 10.1084/jem.20072683

14. Weiss GE, Crompton PD, Li S, Walsh LA, Moir S, Traores B, et al. Atypical memory b cells are greatly expanded in individuals living in a malaria-endemic area. *J Immunol* (2009) 183(3):2176–82. doi: 10.4049/jimmunol.0901297

15. Moir S, Fauci AS. B cell exhaustion in HIV infection: the role of immune activation. *Curr Opin HIV AIDS* (2014) 9(5):472–7. doi: 10.1097/COH.0000000000000192

16. Portugal S, Adjei N, Moir S, Crompton PD, Pierce SK. Atypical memory b cells in human chronic infectious diseases: An interim report. *Cell Immunol* (2017) 321:18–25. doi: 10.1016/j.cellimm.2017.07.003

17. Holla P, Ambegaonkar A, Sohn H, Pierce SK. Exhaustion may not be in the human b cell vocabulary, at least not in malaria. *Immunol Rev* (2019) 292(1):139–48. doi: 10.1111/imr.12809

18. Portugal S, Tipton CM, Sohn H, Kone Y, Wang J, Li S, et al. Malaria-associated atypical memory b cells exhibit markedly reduced b cell receptor signaling and effector function. *Elife* (2015) 4:e07218. doi: 10.7554/eLife.07218

**Supplementary material**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.1087018/full#supplementary-material

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
19. Kardava L, Moir S, Shah N, Wang W, Wilson R, Buckner CM, et al. Abnormal b cell memory subsets dominate HIV-specific responses in infected individuals. J Clin Immunol (2014) 124(7):3252–62. doi: 10.1112/JCI74351

20. Muellenbeck MF, Ueberheide B, Amulic B, Epp A, Fenyo D, Busse CE, et al. Atypical and classical memory b cells produce plasmodium falciparum neutralizing antibodies. J Exp Med (2013) 210(2):389–99. doi: 10.1084/jem.20121970

21. Jardine JG, Kulp DW, Havenar-Daughton C, Sarkar A, Briney B, Sok D, et al. HIV-1 broadly neutralizing antibody precursor b cells revealed by germline-targeting immunogen. Science (2016) 351(6280):1458–63. doi: 10.1126/science.aad9195

22. DiZere AD, Goates EE, Hu Z, Yamshchikov GV, Zaphir KL, Enama ME, et al. An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase 1 clinical trial. NPJ Vaccines (2017) 2:215. doi: 10.1038/s41541-017-0016-6

23. Andrews SF, Joyce MG, Chambers MJ, Gillespie RA, Kanekiyo M, Leung K, et al. Preferential induction of cross-group influenza a hemagglutinin stem-specific memory b cells after H7N9 immunization in humans. Sci Immunol (2017) 2(13):eaan2676. doi: 10.1126/sciimmunol.aan2676

24. Andrews SF, Chambers MJ, Schramm CA, Pyher J, Raab JE, Kanekiyo M, et al. Activation dynamics and immunoglobulin evolution of pre-existing and newly generated human memory b cell responses to influenza hemagglutinin. Immunity (2019) 51(2):398–410 e5. doi: 10.1016/j.immuni.2019.06.024

25. Cale EM, Gorman J, Radakovich NA, Crooks ET, Osawa K, Tong T, et al. Virus-like particles identify an HIV V1V2 apex-binding neutralizing antibody that lacks a protruding loop. Immunity (2017) 46(5):777–91 e10. doi: 10.1016/j.immuni.2017.04.011

26. Zhou T, Lynch RM, Chen L, Acharya P, Yang ZY, Li Y, Hogerkerom CM, et al. Activation dynamics and immunoglobulin evolution of pre-existing and newly generated human memory b cell responses to influenza hemagglutinin. Immunity (2019) 51(2):398–410 e5. doi: 10.1016/j.immuni.2019.06.024

27. Tran TM, Li S, Doumont B, Huang C, Tu S, et al. An intensive longitudinal cohort study of malian children and adults reveals no evidence of acquired immunity to plasmodium falciparum infection. Clin Infect Dis (2015) 61(1):40–7. doi: 10.1093/cid/cit174

28. Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 125(7):1269–81. doi: 10.1016/j.cell.2006.06.008

29. Sok D, Briney B, Jardine JG, Kulp DW, Menis S, Pauthner M, et al. Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. Science (2016) 353(6307):1557–60. doi: 10.1126/science.aah13945

30. Whitlee JR, Wheatley AK, Wu L, Lingwood D, Kanekiyo M, Ma SS, et al. Flow cytometry reveals that HSN1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. J Virol (2014) 88(8):4047–57. doi: 10.1128/JVI.03422-13

31. Wu X, Yang ZY, Li Y, Hogerkerom CM, Schief WR, Seaman MS, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2016) 353(6307):1557–60. doi: 10.1126/science.aab7659

32. Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR V-D-J and V-D-J sequence analysis. Nucleic Acids Res (2008) 36:W503–8. doi: 10.1093/nar/gkn316

33. Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, et al. Geneious basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics (2012) 28(12):1647–9. doi: 10.1093/bioinformatics/bts199

34. Doria Rose N, Bailor R, Louder M, Lin C-L, Turk E, Longo N, et al. High throughput HIV-1 microneutralization assay. (2013). doi: 10.1038/protec.2013.069

35. Montefiori DC. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol (2009) 485:395–405. doi: 10.1007/978-1-59745-170-3_26

36. Sanders RW, Derking R, Cupo A, Julien J-P, Ymseun A, de Val N, et al. A next-generation cleaved, soluble HIV-1 env trimmer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PloS Pathog (2013) 9(9):e1003618. doi: 10.1371/journal.ppat.1003618

37. Caeser R, Di Re M, Krupka JA, Gao J, Lara-Chica M, Dias JML, et al. Genetic modification of primary human b cells to model high-grade lymphoma. Nat Commun (2019) 10(1):4543. doi: 10.1038/s41467-019-12494-x

38. Pinto D, Fenwick C, Caillat C, Silacci C, Guseva S, Deheer F, et al. Structural basis for broad HIV-1 neutralization by the MPER-specific broadly neutralizing antibody LN01. Cell Host Microbe (2012) 26(5):623–37 e8. doi: 10.1016/j.chom.2019.09.016

39. Hopp CS, Sekar P, Dufour A, Miura K, Boswell K, Skinner J, et al. Plasmidium falciparum-specific IgM b cells dominate in children, expand with malaria, and produce functional IgM. J Exp Med (2021) 218(4):e20200901. doi: 10.1084/jem.20200901

40. Boswell KL, Watkins T, Cale EM, Samjel J, Andrews SF, Ambrozak DR, et al. Application of b cell immortalization for the isolation of antibodies and b cell clones from vaccine and infection settings. bioRxiv (2022). doi: 10.1101/2022.03.29.485179